10-Year study tracks heart drug vyndamax in Real-World patients
NCT ID NCT04801329
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is monitoring 110 adults in Korea who are taking Vyndamax (tafamidis) for a rare heart condition called ATTR-CM. The goal is to track side effects and see how well the drug works over 10 years in everyday medical practice. Researchers will check heart function and symptom changes at 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vyndamax (tafamidis) capsules
- What this could lead to
- If successful, this study could confirm that Vyndamax is safe and effective for treating ATTR-CM in real-world Korean patients, supporting its continued use.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. It monitors existing treatment, not testing a new approach, so no major breakthroughs are expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATTR-CM (TRANSTHYRETIN AMYLOID CARDIOMYOPATHY) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.